Pennsylvania Xarelto Lawsuit Puts Forth Unique Allegations

Published on October 20, 2015 by Sandy Liebhard

Text-Size:A A A+


A new Xarelto lawsuit pending in Pennsylvania has put forth allegations unique to the other claims pending in the state’s mass tort litigation. According to court documents, the October 8th filing contends that the blood thinner isn’t always effective for 24 hours, even when taken as directed.

The complaint was filed on behalf of a man who was prescribed the standard 20mg daily dose of Xarelto to prevent strokes associated with nonvalvular atrial fibrillation. Just four days after initiating treatment, he suffered a stroke.

Xarelto Litigation

The Pennsylvania case appears to be the first in the nation to question the effectiveness of standard Xarelto treatment in preventing strokes. But like other Xarelto lawsuits pending in Pennsylvania and elsewhere, the complaint also questions marketing claims that plaintiffs allege wrongly positioned the new-generation blood thinner as a superior alternative to warfarin. Warfarin, sold under the brand Coumadin, has been in use for several decades.

Currently, more than 400 product liability claims are pending in the Xarelto mass tort litigation now underway in the Philadelphia Court of Common Pleas. Nearly 1,700 federal cases have also been filed in a multidistrict litigation now underway in the U.S. District Court, Eastern District of Louisiana. The vast majority of these cases were brought on behalf of plaintiffs who allegedly suffered serious Xarelto bleeding events, such as gastrointestinal or cerebral hemorrhage.

All blood thinners pose a risk of serious internal bleeding. But Xarelto lawsuits point out that warfarin bleeding can be stopped via the administration of vitamin K. By contrast, there is currently no approved antidote to stop internal hemorrhaging caused by Xarelto. Plaintiffs also claim that most Xarelto patients would benefit from regular blood monitoring to ensure that dosage is maintained at an optimum level, something the drug’s manufacturers say is not necessary.

Xarelto is currently the only novel blood thinner that recommends once-daily dosing for atrial fibrillation patients. Other blood thinners on the market require multiple doses each day, and some even recommend that patients undergo regular blood monitoring.

Contact a Xarelto Lawyer Today

The Xarelto lawyers at Bernstein Liebhard LLP are currently representing individuals who suffered serious bleeding events allegedly related to the use of this drug. If you would like to file a similar Xarelto lawsuit, please contact our office by calling (888) 979-1182.

Web Analytics